Capital Analysts LLC Purchases 1,080 Shares of TESARO, Inc. (TSRO)
Capital Analysts LLC boosted its stake in shares of TESARO, Inc. (NASDAQ:TSRO) by 34.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,255 shares of the biopharmaceutical company’s stock after buying an additional 1,080 shares during the period. Capital Analysts LLC’s holdings in TESARO were worth $595,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Botty Investors LLC purchased a new stake in TESARO during the second quarter valued at about $140,000. Meeder Asset Management Inc. purchased a new stake in TESARO during the first quarter valued at about $177,000. BB&T Securities LLC purchased a new stake in TESARO during the second quarter valued at about $222,000. Fox Run Management L.L.C. purchased a new stake in TESARO during the second quarter valued at about $224,000. Finally, World Asset Management Inc purchased a new stake in TESARO during the second quarter valued at about $227,000.
TESARO, Inc. (NASDAQ:TSRO) opened at 124.23 on Wednesday. The company’s market cap is $6.73 billion. The company’s 50-day moving average price is $123.96 and its 200-day moving average price is $146.46. TESARO, Inc. has a 12-month low of $83.26 and a 12-month high of $192.94.
TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.52) by $0.30. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. The business had revenue of $29.50 million for the quarter, compared to analysts’ expectations of $18.61 million. During the same period in the prior year, the company posted ($1.28) earnings per share. The firm’s quarterly revenue was down 17.6% on a year-over-year basis. Equities analysts anticipate that TESARO, Inc. will post ($8.67) earnings per share for the current year.
WARNING: This piece of content was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/30/capital-analysts-llc-purchases-1080-shares-of-tesaro-inc-tsro.html.
Several research firms have issued reports on TSRO. BidaskClub downgraded TESARO from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Robert W. Baird reissued a “neutral” rating on shares of TESARO in a research note on Tuesday, June 6th. Bank of America Corporation reissued a “buy” rating and issued a $154.00 price target on shares of TESARO in a research note on Tuesday, June 20th. Wedbush raised TESARO to an “outperform” rating and set a $168.00 price target on the stock in a research note on Monday, June 5th. Finally, ValuEngine downgraded TESARO from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $175.52.
In other TESARO news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the completion of the sale, the vice president now directly owns 5,396 shares of the company’s stock, valued at $748,155.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 34.60% of the stock is currently owned by corporate insiders.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.